Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

The challenge of herbal therapies for prostate cancer.

Bhatt RS, Bubley GJ.

Clin Cancer Res. 2008 Dec 1;14(23):7581-2. doi: 10.1158/1078-0432.CCR-08-2316. Review.

2.

Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.

Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R.

Cancer Res. 2007 Nov 15;67(22):11083-91.

3.

A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.

Singh RP, Agarwal R.

Mutat Res. 2004 Nov 2;555(1-2):21-32. Review.

PMID:
15476849
4.

Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels.

Verschoyle RD, Greaves P, Patel K, Marsden DA, Brown K, Steward WP, Gescher AJ.

Eur J Cancer. 2008 Apr;44(6):898-906. doi: 10.1016/j.ejca.2008.02.020.

PMID:
18343654
6.

Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy.

Comelli MC, Mengs U, Schneider C, Prosdocimi M.

Integr Cancer Ther. 2007 Jun;6(2):120-9. Review.

PMID:
17548791
7.

Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells.

Jung HJ, Park JW, Lee JS, Lee SR, Jang BC, Suh SI, Suh MH, Baek WK.

Biochem Biophys Res Commun. 2009 Dec 4;390(1):71-6. doi: 10.1016/j.bbrc.2009.09.068.

PMID:
19778521
8.

Complementary and alternative medicine (CAM) in prostate and bladder cancer.

Philippou Y, Hadjipavlou M, Khan S, Rane A.

BJU Int. 2013 Dec;112(8):1073-9. doi: 10.1111/bju.12062. Review.

9.

The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.

Evans S, Dizeyi N, Abrahamsson PA, Persson J.

Anticancer Res. 2009 Oct;29(10):3917-24.

10.

In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.

Ni J, Mai T, Pang ST, Haque I, Huang K, DiMaggio MA, Xie S, James NS, Kasi D, Chemler SR, Yeh S.

Clin Cancer Res. 2009 Feb 1;15(3):898-906. doi: 10.1158/1078-0432.CCR-08-1087.

11.

The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.

Said N, Frierson HF Jr, Chernauskas D, Conaway M, Motamed K, Theodorescu D.

Oncogene. 2009 Oct 1;28(39):3487-98. doi: 10.1038/onc.2009.205.

PMID:
19597474
12.

PC-SPEC, an herbal remedies use in patients with hormone-refractory prostate cancer.

[No authors listed]

Home Healthc Nurse. 2003 Jun;21(6):363. No abstract available.

PMID:
12841183
13.
14.

Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression.

Jones E, Pu H, Kyprianou N.

Expert Opin Ther Targets. 2009 Feb;13(2):227-34. doi: 10.1517/14728220802705696 . Review.

PMID:
19236240
15.

Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.

Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, Ling MT, Wong YC.

Clin Cancer Res. 2009 Jul 1;15(13):4322-35. doi: 10.1158/1078-0432.CCR-08-3157.

16.

PC-SPES for treatment of prostate cancer: herbal medicine.

Yip I, Cudiamat M, Chim D.

Curr Urol Rep. 2003 Jun;4(3):253-7. Review.

PMID:
12756091
17.
18.

Noscapine inhibits human prostate cancer progression and metastasis in a mouse model.

Barken I, Geller J, Rogosnitzky M.

Anticancer Res. 2008 Nov-Dec;28(6A):3701-4.

20.

Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.

Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.

Chin Med J (Engl). 2008 Nov 20;121(22):2284-9.

PMID:
19080333

Supplemental Content

Support Center